Item 7.01 Regulation FD Disclosure.

On June 28, 2021, Taysha Gene Therapies, Inc. (the "Company") will host the first day of a two-day virtual research and development day (the "R&D Day") for analysts and investors to highlight the Company's research and development progress, focused on advancement of its early- and late-stage investigational programs. A copy of the presentation, dated June 28, 2021, that the Company intends to use on the first day of the Company's R&D Day is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



             Exhibit
               No.     Description

             99.1        Company presentation, dated June 28, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses